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MTRRAbstract Background: Down syndrome (DS), also called as trisomy 21, is one of the most leading
cause of intellectual disability. DS is associated with a number of phenotypes including Congenital
Heart Disease (CHD), Leukemia, Alzheimer’s disease, Hirschsprung’s disease and others. DS
affects about 1 in 700 live births.
Objectives: The study aims to investigate the association of MTRR (Methionine synthase
reductase) gene polymorphisms (C524T and A66G) with the risk of CHD in DS patients.
Methods: PCR and PCR-RFLP methods were used for the genotyping of study samples and
results were validated using Sanger’s sequencing.
Results: MTRR C524T and A66G were significantly associated with the increased risk of CHD
in DS. We have also reported two novel polymorphisms, T19775C and 19778_19778delG, in DS
with CHD cases with a frequency of 93% and 40%, respectively. These two polymorphisms were
not found among DS without CHD group.
Conclusion: Results from this study indicate that the MTRR C524T and A66G polymorphisms
influence the risk of the occurrence of CHD in DS patients of Indian Origin. This is the first report
from India highlighting the potential association of MTRR C524T and A66G polymorphisms with
CHD in DS. We are also the first one to report two novel polymorphisms, T19775C and
19778_19778delG in DS with CHD group. Hence these four polymorphisms can be used to evaluate
the risk of CHD in DS patients.
 2016 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)..
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2 A. Asim et al.1. Introduction
Down syndrome (DS), also referred to as trisomy 21, is
associated with various birth defects like congenital mental
disability, hypotonia, Congenital Heart Disease (CHD),
Hirschsprung’s disease and others. The frequency and severity
of these morphological defects vary significantly among
affected individuals. DS affects about 1 in 700 live births [1,2].
CHD is a common disorder among newborn infants [3]
which can be caused by environmental or genetic factors.
About 50% of babies with DS are born with CHD, which is
a much higher percentage compared to 1% of children born
with CHD without DS. The most common CHD seen in DS
patients is atrioventricular septal defect (AVSD). Other com-
mon heart defects include ventricular septal defects (VSD),
atrial septal defects (ASD), tetralogy of fallot (TOF) and
patent ductus arteriosus (PDA). However, the exact etiology
of CHD in DS remains poorly understood.
Recently, several studies indicated that a gene involved in
homocysteine metabolism, methylenetetrahydrofolate reduc-
tase (MTHFR), is an important candidate gene for influenc-
ing the risk of CHD in DS [4–9,14]. However, only a few
studies are reported indicating the role of another gene
involved in homocysteine metabolism, Methionine synthase
reductase (MTRR), in context with CHD in DS [5,9–14].
No such studies have been published from India highlighting
the importance of MTRR gene in the occurrence of CHD in
DS patients.
MTRR is a key enzyme in folate dependent homocysteine
metabolism and its gene is located on chromosome
5p15.2–15.3 [15]. MTRR catalyzes the conversion of the inac-
tive form of methionine synthase (MTR) into its active form,
by the regeneration of methyl (III) cobalamin, the cofactor
of MTR. The disturbances in its catalytic activity lead to a
higher level of homocysteine. The most common polymor-
phism in MTRR gene is A66G (rs1801394) substitution [16],
leading to a change of isoleucine to methionine in amino acid
22 (I22M). The I22M variant is located in the putative
FMN-binding domain of the MTRR enzyme that is suggested
to interact with MTR. Substitution in this part of the enzyme
thus disrupted the binding of MTRR to the MTR-cobalamin-
complex, thereby decreasing the rate of homocysteine remethy-
lation [16,17]. Another polymorphism C524T (rs1532268)
leads to an amino acid change from serine to leucine
(S175L). Since no results are available from India, we investi-
gated the association of the two polymorphisms of MTRR
gene with the occurrence of CHD in DS.
2. Subjects and methods
2.1. Subjects
Sixty DS with CHD patients and sixty patients DS without
CHD were recruited in this study from the Department of
Advanced Pediatric Center, Post Graduate Institute of
Medical Education andResearch, Chandigarh andDepartment
of Medical Genetics, Sanjay Gandhi Post Graduate Institute of
Medical Sciences, Lucknow. Exclusion criteria were race other
than Indian. The work has been carried out in accordance with
the code of Ethics of the World Medical association
(Declaration of Helsinki) for experiments in humans.Please cite this article in press as: Asim A et al., MTRR gene variants may predispos
origin, Egypt J Med Hum Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.02.02.2. Genotyping of MTRR gene
Peripheral venous blood was taken in EDTA coated vial and
the genomic DNA was isolated using standard Phenol
Chloroform method. Predesigned primers were used to
amplify MTRR gene for both the variants using PCR (condi-
tions given in Table 1). The temperature profile used in PCR
for both the polymorphisms were performed using initial
denaturation at 95 C for 5 min, followed by 35 cycle at
95 C for 30 s, at 59 C for 30 s, at 72 C for 30 s and final
extension at 72 C for 10 min. The PCR amplified products
were digested using restrictions enzymes (Xho I for C524T
and Nde I for A66G) and was kept at 37 C overnight followed
by the electrophoresis on a 3.5% agarose gel. In order to verify
the genotypes by PCR-RFLP, the purified PCR products of
random samples selected were sequenced directly. (AB
Sequence Detection System 310 software package; Applied
Biosystems).
2.3. Statistical analyses
Genotype and allele frequency distributions of two polymor-
phisms in the MTRR gene were compared between patients
of DS with CHD and DS without CHD, using the chi-
square test. The odds ratios (OR) were calculated with the
95% confidence intervals (95%CI). All analyses were per-
formed using SPSS for Windows, version 16.0. The p-values
were considered to be significant at 0.05.
3. Results
3.1. Frequency and genotyping of the MTRR C524T
polymorphism
Through PCR-RFLP and Sanger’s sequencing, MTRR C524T
polymorphism was evaluated using Xho I restriction enzyme
which digest the PCR amplified products, thereby dividing into
three genotypes, CC (247 bp and 62 bp), CT (309 bp, 247 bp
and 62 bp) and TT (309 bp) (Fig. 1). The allelic and genotype
frequencies are summarized in Tables 2a and 2b. The fre-
quency of T allele was slightly higher in DS with CHD
(C = 51%; T = 33%) patients when compared to DS with
CHD patients (C= 54%; T= 30%; p= 0.66). The genotype
frequencies of DS with CHD and DS without CHD were
CC = 44%, CT = 36%, TT = 20% and CC = 59%,
CT = 6% and TT = 31%, respectively (p-value = 0.002).
3.2. Frequency and genotyping of the MTRR A66G
polymorphism
Similarly, through PCR-RFLP and Sanger’s sequencing,
MTRR A66G polymorphism was evaluated using Nde I
restriction enzyme which digests the PCR amplified products,
thereby dividing into three genotypes- AA (126 bp, 25 bp),
AG (151 bp, 126 bp, 25 bp) GG (151 bp, Fig. 2). The allelic
and genotype frequencies are summarized in
Tables 2a and 2b. The frequency of A allele was slightly higher
in DS with CHD (A= 53%; G= 31%) patients when com-
pared to DS without CHD patients (A= 45%; G= 38%;
p< 0.0001). The genotype frequencies of DS with CHD and
DS without CHD patients were AA= 43%, AG= 24%,e to the risk of Congenital Heart Disease in Down syndrome patients of Indian
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Table 1 Shows the conditions of PCR.
Variants Primers Annealing
temp (C)
Amplification
fragments
(bp)
Restriction
enzymes
Genotypes
MTRR c. 524
C> T
F-50-TCAAGCAGAGGACAAGAG-3
R-50AGAGACTCCTGCAGATGTAC-30
59 309 Xho I CC-247 bp, 62 bp
CT-309 bp, 247 bp, 62 bp
TT-309 bp;
MTRR c. 66
A> G
F-50-GGCAAAGGCCATCGCAGAAGACAT-30
R-50CACTTCCCAACCAAAATTCTTCAAAG-30
59 151 Nde I AA-126 bp, 25 bp
AG – 151 bp, 126 bp,
25 bp GG-151 bp
Figure 1 (A) shows the PCR digest fragments using Xho I enzymes separated on agarose gel showing CT genotype ofMTRR c. 524C>T
variant of band size of 309 bp and 247 bp. Lane M shows molecular marker. (B) and (C) shows the confirmation by Sanger’s sequencing
showing CC and TT genotype, respectively.
Table 2a Frequencies of allelic and genotypic MTRR C524T genetic variants.
Groups Genotypic frequency % (n) Allelic frequency % (n)
CC CT TT p C T p
DS with CHD (N= 60) 44 (26) 36 (22) 20 (12) 0.002 51 (61) 33 (39) 0.66
DS without CHD (N= 60) 59 (35) 10 (6) 31 (19) 54 (64) 30 (36)
p< 0.001 is considered as significant.
Table 2b Frequencies of allelic and genotypic MTRR A66G genetic variants.
Groups Genotypic frequency % (n) Allelic frequency % (n)
AA AG GG p A G p
DS with CHD (N= 60) 43 (26) 40 (24) 16 (10) <0.0001 53 (64) 31 (37) p< 0.001
DS without CHD (N= 60) 53 (32) 2 (1) 45 (27) 45 (54) 38 (46)
p< 0.001 is considered as significant.
MTRR gene variants may predispose to the risk of Congenital Heart Disease 3GG= 10% and AA= 53%, AG= 2% and GG= 45%,
respectively (p-value < 0.001).
3.3. Novel polymorphism in MTRR gene
Sanger’s sequencing revealed two novel MTRR gene polymor-
phisms in DS with CHD cases. The first polymorphism isPlease cite this article in press as: Asim A et al., MTRR gene variants may predispos
origin, Egypt J Med Hum Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.02.0C19775T which was found at exon intron junction in MTRR
gene with the frequency of 93% (n= 56) in DS with CHD
cases. The second polymorphism is a deletion
g.19778_19778delG which was also found at exon intron junc-
tion inMTRR gene with the frequency of 63% (n= 40) in DS
with CHD cases. Both of the polymorphisms were predicted as
disease by MutationTaster software. These polymorphismse to the risk of Congenital Heart Disease in Down syndrome patients of Indian
06
Figure 2 (A) shows the PCR digest fragments using Nde I enzymes separated on agarose gel showing AG genotype ofMTRR C. 66A>G
variant of band size of 151 bp and 126 bp. Lane M shows molecular marker. (B) and (C) shows the confirmation by Sanger’s sequencing
showing AA and TT genotype, respectively.
Figure 3 Shows the Sanger’s sequencing result of novel
polymorphisms.
Table 3a Association of MTRR C524T polymorphisms with
the risk of CHD in DS.
Comparisons Tests of associations
OR (95% CI) v2 p
Homozygote comparison
(CC Vs TT)
0.85 (0.35–2.05) 0.12 0.70
Heterozygote comparison
(CC Vs CT)
4.94 (1.75–13.91) 9.98 p< 0.01
Dominant model
(CC Vs CT+ TT)
1.9 (0.95–2.01) 3.0 0.08
Recessive model
(CC+ CT Vs TT)
0.53 (0.23–1.24) 2.13 0.14
Allele contrast (C Vs T) 1.13 (1.71–6.65) 0.19 0.0003
Table 3b Association of MTRR A66G polymorphism with
the risk of CHD in DS.
Comparisons Tests of associations
OR (95% CI) v2 p
Homozygote
comparison (AA Vs GG)
0.45 (0.18–1.11) 3.04 0.08
Heterozygote
comparison (AA Vs AG)
13.33 (1.59–111.3) 8.4 <0.0001
Dominant model
(AA Vs AG+ GG)
1.49 (0.73–3.07) 1.20 0.20
Recessive model
(AA+ AG Vs GG)
0.24 (0.10–0.57) 11.2 <0.0001
Allele contrast
(A Vs G)
0.66 (0.35–1.19) 0.81 0.2
4 A. Asim et al.were not found in DS without CHD group. The sequence
obtained was thoroughly scanned and compared against the
published sequence of MTRR. (Table 4 and Fig. 3).
3.4. Association of risk of MTRR polymorphisms with the risk
of CHD in DS
The association of the MTRR C524T polymorphism with the
risk of the occurrence of CHD in DS is shown in Table 3a. Our
data suggested that this polymorphism was associated with the
increased risk of CHD with DS in a heterozygote comparison
(CT Vs CC; OR= 4.9 (95% CI: 1.75–13.9; k2 = 9.9;
p= 0.001) and dominant model (CC Vs CT+ TT;
OR= 1.9 (95% CI: 0.95–2.01; k2 = 3; p= 0.08), while mod-
els like allele contrast (C Vs T; OR= 3.37 (95% CI:
1.71–6.65, k2 = 13, p= 0.0003) and homozygote comparison
(CC Vs TT; OR= 0.85 (95% CI: 0.35–2.05, k2 = 0.12,
p= 0.7) do not shown much association.
Similarly, the association of the MTRR A66G polymor-
phisms with the risk of CHD in DS cases is shown in
Table 3b. Our data suggested that this polymorphism wasPlease cite this article in press as: Asim A et al., MTRR gene variants may predispos
origin, Egypt J Med Hum Genet (2016), http://dx.doi.org/10.1016/j.ejmhg.2016.02.0associated with the increased risk of CHD in DS cases in a
heterozygote comparison (AG Vs AA; OR= 13.3 (95% CI:
1.59–111; k2 = 8.4; p< 0.001) and in dominant model (AG
+ GG Vs AA; OR= 1.49 (95% CI: 0.73–3.07, k2 = 1.2,
p= 0.20), while models like homozygote (AA Vs GG;
OR= 0.45 (95% CI: 0.18–1.11 k2 = 3.04, p value = 0.08);
recessive model (GG Vs AG+ AA; OR= 0.24 (95% CI:
0.10–0.57, k2 = 11.2, p= 0.0008), dominant, and allele
contrast (A Vs G; OR= 0.6 (95% CI: 0.385–1.19, k2 = 0.81,
p= 0.2) do not show much association.e to the risk of Congenital Heart Disease in Down syndrome patients of Indian
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Table 4 showing novel polymorphisms detected in MTRR gene in DS with CHD.
SNP Nature of mutation MutationTaster software Study group frequency (n/%); N= 60
g.19775T> C Intron exon Junction Disease causing DS with CHD= 56/93%;DS without CHD= 0
g.19778_19778delG Deletion of G Disease causing DS with CHD= 40/67%; DS without CHD= 0
MTRR gene variants may predispose to the risk of Congenital Heart Disease 54. Discussion
The association between DS and CHD has been well estab-
lished since 1950, when the incidence of CHD present in DS
patients was thoroughly described [18]. Since then several
cohort studies [19,20] have significantly contributed to the
close relationship between DS and CHD. The same studies
have also demonstrated that the types of CHD most com-
monly associated with trisomy 21 are AVSD and VSD, which
together account for 76% of all CHD seen in DS patients [20].
Only some DS patients have other defects such as ventricular
septal defects (VSD), atrial septal defects (ASD), tetralogy of
fallot (TOF) and patent ductus arteriosus (PDA).
CHD in DS is a complex interaction between environmental
and genetic factors. Furthermore, growing evidence indicated
that the genetic factors play an important role in the develop-
ment of CHD in DS. One of the examples of genetic factor like
MTHFR has been studied and reported that MTHFR, which is
involved in the homocysteine pathway, is one of the most
important candidate genes for influencing the susceptibility to
CHD in DS. However, only a few studies have been reported
emphasizing the role of MTRR which is another important
gene involved in homocysteine pathway [21–24].
In present study, firstly we investigated the distribution of
MTRR C524T polymorphisms by PCR-RFLP and evaluated
the influence of these two polymorphisms on the risk of occur-
rence of CHD in DS patients of the Indian population through
the association of DS without CHD patients. Our findings sug-
gested that the results were significant for allelic and genotype
frequencies for CHD in DS cases and non CHD controls
(Tables 2a, 2b, 3a and 3b).
In conclusion, to our knowledge, we are the first to investi-
gate the potential association of MTRR C524T and MTRR
A66G polymorphisms with the risk of the occurrence of
CHD in DS patients of Indian origin. Further Sanger’s
sequencing was also performed to validate the results. The
results from this study suggests that MTRR C524T and
A66G polymorphisms are associated with the increased risk
of CHD in DS patients of Indian origin and could be used
as a genetic marker for evaluating the occurrence of CHD in
DS. Further studies with larger different ethnic populations
are needed to confirm same results in their ethnicity.
We have also identified two novel polymorphisms T19775C
and 19778_19778delG, in DS with CHD patients with a high
frequency. These two polymorphisms were not present in DS
without CHD patients which suggest the role of these poly-
morphisms in the occurrence of CHD in DS patients of Indian
origin. Hence these two polymorphism along with A66G and
C524T should be considered as markers for CHD in DS.Competing interest
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